See analyst estimates and all valuation multiples for Regenerative Medicine
| Company | EV | EV/LTM Revenue | EV/LTM EBITDA |
|---|---|---|---|
| $110B | n/a | n/a | |
| $10.5B | n/a | n/a | |
| $6.4B | n/a | n/a | |
| $4.6B | 7.3x | 42.7x | |
| $4.1B | 1178.5x | -245.9x | |
| $3.4B | n/a | n/a | |
| $2.8B | 7.2x | 16.5x | |
| $2.3B | n/a | n/a | |
| $1.8B | n/a | n/a | |
| $1.8B | n/a | n/a | |
| $1.5B | n/a | n/a | |
| $1.5B | n/a | n/a | |
| $1.5B | 570.2x | -14.2x | |
| $839M | n/a | -32.5x | |
| $836M | 2.1x | 8.3x | |
| $829M | n/a | n/a | |
| $696M | n/a | n/a | |
| $654M | 11.6x | -1.5x | |
| $581M | n/a | n/a | |
| $461M | n/a | n/a | |
| $340M | 33.6x | -9.5x | |
| $304M | 24.3x | -87.7x | |
| $292M | 260.8x | n/a | |
| $216M | n/a | n/a | |
| $193M | n/a | n/a | |
| $185M | 23.4x | -32.7x | |
| $177M | 717.2x | -0.8x | |
| $159M | n/a | n/a | |
| $157M | n/a | n/a | |
| $101M | 0.9x | 60.0x | |
| $101M | n/a | n/a | |
| $87.6M | n/a | n/a | |
| $69.0M | n/a | n/a | |
| $60.8M | 667.9x | n/a | |
| $53.0M | n/a | n/a | |
| $51.9M | 2.8x | -5.8x | |
| $51.6M | n/a | -4.2x | |
| $48.2M | 94.6x | -0.3x | |
| $46.9M | n/a | n/a | |
| $41.8M | n/a | n/a | |
| $30.5M | n/a | n/a | |
| $18.2M | n/a | n/a | |
| $15.2M | n/a | n/a | |
| $13.3M | 2.9x | n/a | |
| $4.4M | n/a | n/a | |
| -$56.6M | -0.6x | 0.4x |
Valuation multiples as of last 12 months (LTM). Financial data powered by Morningstar, Inc.
See analyst estimates and M&A multiples for Regenerative Medicine